Buscar
01/12/2021
Alpha variant SARS-CoV-2 infection: How it all starts
Domingo, P, de Benito, N. Alpha variant SARS-CoV-2 infection: How it all starts. EBioMedicine. 2021; 74DOI:10.1016/j.ebiom.2021.103703. PMID:34800902. IF:11.205(Q1/2D).
01/11/2025
Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in Spain
Camps-Vilaró, A, Teira, R, Subirana, I, Dégano, IR, Domingo, P, Curran, A, Montero-Alonso, M, Romero, A, Marrugat, J, Galindo, MJ. Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in Spain. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025; 160DOI:10.1016/j.ijid.2025.108061. PMID:40953693. IF:4.300(Q1/2D).
01/08/2025
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
de Lazzari, E, Di Gregorio, S, Rojas, J, Curran, A, Domingo, P, Negredo, E, Tiraboschi, J, Gonzalez-Cordon, A, Torres, B, Sempere, A, Inciarte, A, Gatell, JM, Blanco, JL, Martinez, E. 48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2025; 80(8)DOI:10.1093/jac/dkaf192. PMID:40556520. IF:3.600(Q2/3D).
08/07/2025
Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions
Giralt, M, Domingo, P, Quesada-López, T, Cereijo, R, Villarroya, F. Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(14)DOI:10.3390/ijms26146546. PMID:40724797. IF:4.900(Q1/3D).
01/07/2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial
Ryan, P, Blanco, JL, Masia, M, Garcia-Fraile, L, Crusells, MJ, Domingo, P, Curran, A, Guerri-Fernandez, R, Bernal, E, Bravo, J, Revollo, B, Macias, J, Tiraboschi, JM, Montejano, R, Amador, C, Torralba, M, Merino, D, Diaz-Brito, V, Galindo, MJ, Ferra, S, Villoslada, A, Losa, JE, Fanjul, FJ, Perez-Stachowski, X, Peraire, J, Portilla, J, de la Fuente, S, Dueñas, C, Vazquez, MJ, Di Gregorio, S, Esteban, H, Gil, P, de Miguel, M, Alejos, B, Martínez, E. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV. 2025; 12(7)DOI:10.1016/S2352-3018(25)00105-5. PMID:40489982. IF:13.000(Q1/1D).
01/04/2025
Antiviral effect, safety, and tolerability of the third-generation integrase strand transfer inhibitor VH4524184 (VH-184): a proof-of-concept trial
Rogg, L, Nuñez, SA, Mingrone, MVO, Domingo, P, Lopez, M, Hanan, N, Ghita, GL, Jeffrey, JL, Underwood, M, Castillo-Mancilla, JR, Halliday, F, Ezeadi, E, Gartland, M. Antiviral effect, safety, and tolerability of the third-generation integrase strand transfer inhibitor VH4524184 (VH-184): a proof-of-concept trial. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).